Imaginostics is a brand that specializes in innovative diagnostic solutions. They utilize breakthrough quantitative imaging biomarkers to provide new insights into health and disease through non-invasive methods. Their goal is to advance patient care by offering safe and effective quantitative imaging technology.

Imaginostics offers a range of products and services. Their technology and software are compatible with existing MRI scanners and hardware, allowing for the visualization of vasculature, health and disease assessment, patient stratification, early preventative diagnostics, and drug efficacy assessment in clinical trials. The brand also actively collaborates in pre-clinical and clinical research, particularly in the areas of neuroscience, cancer, and cardiology.

They are open to new partnerships with academic investigators, further expanding their research capabilities. Imaginostics has received noteworthy recognition in the field. They have been awarded grants, including a $915k NIH-NIA SBIR Grant for the clinical validation of their novel MRI biomarkers in screening and quantification of dementia.

To stay up-to-date with Imaginostics' latest developments, interested individuals can subscribe to their newsletter. For inquiries, the brand can be contacted through their website. Imaginostics is dedicated to revolutionizing diagnostics through innovative technology, contributing to advancements in patient care and research